Dexpramipexole Is Ineffective in Two Models of ALS Related Neurodegeneration

• Fernando G. Vieira ,

  Contributed equally to this work with: Fernando G. Vieira, Eva LaDow

  * E-mail: fvieira@als.net (FGV); sfinkbeiner@gladstone.ucsf.edu (SF)

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Eva LaDow ,

  Contributed equally to this work with: Fernando G. Vieira, Eva LaDow

  Affiliation Gladstone Institute of Neurological Disease, San Francisco, California, United States of America

  ⨯
• Andy Moreno,

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Joshua D. Kidd,

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Beth Levine,

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Kenneth Thompson,

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Alan Gill,

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯
• Steven Finkbeiner ,

  * E-mail: fvieira@als.net (FGV); sfinkbeiner@gladstone.ucsf.edu (SF)

  Affiliations Gladstone Institute of Neurological Disease, San Francisco, California, United States of America, Taube-Koret Center for Neurodegenerative Disease Research and the Hellman Family Foundation Alzheimer's Disease Research Program, San Francisco, California, United States of America, Departments of Neurology and Physiology, University of California San Francisco, San Francisco, California, United States of America

  ⨯
• Steven Perrin

  Affiliation ALS Therapy Development Institute, Cambridge, Massachusetts, United States of America

  ⨯